{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-234395","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.248237+00:00","generated_at":"2026-06-10T18:51:06.431300+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Madrigal appoints Bill Sibold as President & CEO, effective Sept 8, 2023","bullets":["Bill Sibold appointed President & CEO effective Sept 8, 2023; also joins Board as Class II director.","Sibold compensation: $875k base salary, 75% target bonus, $520k sign-on cash, 50k time-based RSUs, 50k performance PSUs.","Former CEO Paul Friedman steps down but remains on Board; receives 12 months base salary plus 100% of target bonus.","Sibold previously EVP Specialty Care at Sanofi; prior roles at Biogen, Avanir. Yale BA, Harvard MBA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-234395","json":"https://secwatch.observer/filing/0001193125-23-234395.json","markdown":"https://secwatch.observer/filing/0001193125-23-234395.md","text":"https://secwatch.observer/filing/0001193125-23-234395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/0001193125-23-234395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/d444513d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T18:51:06.431300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a99bac53f","claim":"Bill Sibold was appointed as President and Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"The Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the “Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/0001193125-23-234395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fad3226682","claim":"Paul Friedman departed as Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"As of the Start Date, Dr. Friedman stepped down as Chief Executive Officer but will continue to serve as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523234395/0001193125-23-234395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}